160. 先天性魚鱗癬 Disease details / Clinical trials / Drug dev / DR info

1643368-58-4
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2017   Phase 2   EUCTR2016-000101-37-IT   Belgium;Chile;Colombia;Denmark;France;Greece;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
   Bristol-Myers Squibb International Corporation
      2017   Phase 2   EUCTR2016-000101-37-GR   Belgium;Chile;Colombia;Denmark;France;Greece;Hungary;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
Abatacept
   Bristol-Myers Squibb International Corporation
      2017   Phase 3   EUCTR2016-001948-19-SE   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
      2016   Phase 3   EUCTR2016-001948-19-FR   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
      2016   Phase 3   EUCTR2016-001948-19-CZ   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
Active topical NS2 1% dermatologic cream
   Aldeyra Therapeutics, Inc.
      2015   Phase 2   NCT02402309   United States
Adalimumab
   Assistance Publique - Hôpitaux de Paris
      2014   Phase 2   NCT02113904   France
ADX-629
   University of Nebraska
      2023   Phase 1/Phase 2   NCT05443685   United States
ANTI-CD28DAB
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2017   Phase 2   EUCTR2016-000101-37-IT   Belgium;Chile;Colombia;Denmark;France;Greece;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
   Bristol-Myers Squibb International Corporation
      2017   Phase 2   EUCTR2016-000101-37-GR   Belgium;Chile;Colombia;Denmark;France;Greece;Hungary;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
Apply veregen ® 10 % ON A randomized area and THE moisturizing cream OF THE other side
   Centre Hospitalier Universitaire de Nice
      2010   Phase 3   NCT01222000   France
Atorvastatin
   Department of Dermatology, Keio University School of Medicine
      2013   -   JPRN-UMIN000012355   Japan
   Kubo Akiharu
      2013   Phase 2   JPRN-jRCTs031180409   -
ATR12-351
   Azitra Inc.
      2024   Phase 1   NCT06137157   United States
BCX17725
   BioCryst Pharmaceuticals
      2024   Phase 1   NCT06539507   Australia
Bezafibrate
      2011   -   EUCTR2011-001205-27-NL   Netherlands
Bezalip retard
      2011   -   EUCTR2011-001205-27-NL   Netherlands
BMS-188667
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2017   Phase 3   EUCTR2016-001948-19-IT   Argentina;Australia;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
   Bristol-Myers Squibb International Corporation
      2017   Phase 3   EUCTR2016-001948-19-SE   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
      2016   Phase 3   EUCTR2016-001948-19-FR   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
      2016   Phase 3   EUCTR2016-001948-19-CZ   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
BMS-931699
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2017   Phase 2   EUCTR2016-000101-37-IT   Belgium;Chile;Colombia;Denmark;France;Greece;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
   Bristol-Myers Squibb International Corporation
      2017   Phase 2   EUCTR2016-000101-37-GR   Belgium;Chile;Colombia;Denmark;France;Greece;Hungary;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
BMS-986142
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2017   Phase 2   EUCTR2016-000101-37-IT   Belgium;Chile;Colombia;Denmark;France;Greece;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
   Bristol-Myers Squibb International Corporation
      2017   Phase 2   EUCTR2016-000101-37-GR   Belgium;Chile;Colombia;Denmark;France;Greece;Hungary;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
BMS986142
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2017   Phase 2   EUCTR2016-000101-37-IT   Belgium;Chile;Colombia;Denmark;France;Greece;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
   Bristol-Myers Squibb International Corporation
      2017   Phase 2   EUCTR2016-000101-37-GR   Belgium;Chile;Colombia;Denmark;France;Greece;Hungary;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
BPR277
   Novartis Pharma Services AG
      2013   -   EUCTR2011-000917-38-NL   France;Germany;Netherlands;United States
      2011   -   EUCTR2011-000917-38-DE   France;Germany;Netherlands;United States
BPR277 ointment
   Novartis Pharmaceuticals
      2011   Phase 1   NCT01428297   France;Germany;Netherlands;United States
BTK inhibitor
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2017   Phase 2   EUCTR2016-000101-37-IT   Belgium;Chile;Colombia;Denmark;France;Greece;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
   Bristol-Myers Squibb International Corporation
      2017   Phase 2   EUCTR2016-000101-37-GR   Belgium;Chile;Colombia;Denmark;France;Greece;Hungary;Italy;Mexico;Netherlands;Norway;Peru;Poland;Romania;Russian Federation;South Africa;United Kingdom;United States
Cholesterol
   Department of Dermatology, Keio University School of Medicine
      2013   -   JPRN-UMIN000012355   Japan
   Kubo Akiharu
      2013   Phase 2   JPRN-jRCTs031180409   -
CNT-02
   Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
      2016   -   NCT02830763   Italy;Japan
Deucravacitinib
   Centre Hospitalier Universitaire de Nice
      2023   Phase 2   NCT06136403   France
DS-2325A
   Daiichi Sankyo
      2023   Phase 1/Phase 2   NCT05979831   France
   Daiichi Sankyo, Inc.
      2022   Phase 1   NCT05583669   United States
      2022   Phase 1   NCT05388903   United States
Dupilumab
   CHU de Toulouse
      2019   Phase 2   EUCTR2019-001220-35-FR   France
Dupilumab injection
   National Medical Research Center for Children's Health, Russian Federation
      2021   Phase 4   NCT04996485   Russian Federation
Dupilumab prefilled syringe
   University Hospital, Toulouse
      2020   Phase 2/Phase 3   NCT04244006   France
Dupixent
   CHU de Toulouse
      2019   Phase 2   EUCTR2019-001220-35-FR   France
Epithelial sheet generated from transduced autologous keratinocytes using PCCL-INVO-SP
   GOSH/ICH Joint Research & Development Office
      2013   Phase 1   EUCTR2011-003212-22-GB   United Kingdom
Erlotinib
   Northwestern University
      2025   Phase 1/Phase 2   NCT06545695   United States
Fibrate treatment
   Maastricht University Medical Center
      2011   Phase 4   NCT01527318   Netherlands
Hematopoetic stem cell transplantation
   University of Pittsburgh
      2012   -   NCT03333200   United States
Humira
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2013   -   EUCTR2013-002205-54-FR   France
Isotretinoin
   Timber Pharmceuticals LLC
      2019   Phase 2   NCT04154293   Australia;United States
Isotretinoina
   Timber Pharmaceuticals, Inc
      2022   Phase 3   EUCTR2022-000459-35-IT   Canada;France;Germany;Italy;United States
Ixekizumab
   Dermatology Hospital of Southern Medical University
      2022   Phase 2   ChiCTR2200059272   China
KB105
   Krystal Biotech, Inc.
      2023   Phase 2   NCT05735158   United States
      2019   Phase 1/Phase 2   NCT04047732   United States
L04ab04
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2013   -   EUCTR2013-002205-54-FR   France
Lipoxygenase inhibitor
   UMC St Radboud
      2009   Phase 3   EUCTR2009-015895-87-NL   Netherlands
Lovastatin
   Northwestern University
      2011   Phase 2   NCT01110642   United States
Monolaurin cream
   Cellegy Pharmaceuticals
      1996   Phase 3   NCT00004690   -
ONE 20cm2/10cm2 autologous skin sheet graft
   Great Ormond Street Hospital for Children NHS Foundation Trust
      2014   Phase 1   NCT01545323   United Kingdom
Oral glucose tolerance test
   University Hospital, Toulouse
      2015   -   NCT02383316   France
Orencia
   BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATION
      2017   Phase 3   EUCTR2016-001948-19-IT   Argentina;Australia;Brazil;Canada;Czech Republic;Czechia;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
   Bristol-Myers Squibb International Corporation
      2017   Phase 3   EUCTR2016-001948-19-SE   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
      2016   Phase 3   EUCTR2016-001948-19-FR   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
      2016   Phase 3   EUCTR2016-001948-19-CZ   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
Oxiconazole
   Department of Dermatology, Keio University School of Medicine
      2013   -   JPRN-UMIN000012355   Japan
   Kubo Akiharu
      2013   Phase 2   JPRN-jRCTs031180409   -
Palliative care
   University of Pittsburgh
      2012   -   NCT03333200   United States
PAT
   Patagonia Pharmaceuticals, LLC
      2017   Phase 2   NCT02864082   United States
Pimecrolimus 1% cream
   Children's Hospital of Philadelphia
      2005   Phase 1/Phase 2   NCT00208026   United States
PRE-filled syringe
   Bristol-Myers Squibb International Corporation
      2017   Phase 3   EUCTR2016-001948-19-SE   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
      2016   Phase 3   EUCTR2016-001948-19-FR   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
      2016   Phase 3   EUCTR2016-001948-19-CZ   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Norway;Sweden
QRX003, 4% lotion
   Quoin Pharmaceuticals
      2025   Phase 2/Phase 3   NCT06953466   United States
      2023   Phase 2/Phase 3   NCT05789056   United States
QRX003-2% lotion
   Quoin Pharmaceuticals
      2022   Phase 2/Phase 3   NCT05521438   United States
QRX003-4% lotion BID
   Quoin Pharmaceuticals
      2022   Phase 2/Phase 3   NCT05521438   United States
QRX003-4% lotion QAM
   Quoin Pharmaceuticals
      2022   Phase 2/Phase 3   NCT05521438   United States
Reproxalap
   Aldeyra Therapeutics, Inc.
      2018   Phase 3   NCT03445650   United States
RVG 18388
      2011   -   EUCTR2011-001205-27-NL   Netherlands
SAR231893
   CHU de Toulouse
      2019   Phase 2   EUCTR2019-001220-35-FR   France
Secukinumab
   Northwestern University
      2016   Phase 2   NCT03041038   United States
Secukinumab injection
   National Medical Research Center for Children's Health, Russian Federation
      2021   Phase 4   NCT04996485   Russian Federation
Simvastatin
   Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
      2020   Phase 0   ChiCTR2000037278   China
Spesolimab
   Taguchi Aya
      2023   Phase 2-3   JPRN-jRCT2031220722   Australia;Austria;Belgium;Bulgaria;China;Czech Republic;Finland;France;Germany;Israel;Italy;Japan;Malaysia;Netherlands;Portugal;Spain;Switzerland;United Kingdom;United States
Spesolimab - solution FOR infusion
   Boehringer Ingelheim
      2023   Phase 2/Phase 3   NCT05856526   Australia;Austria;Belgium;Bulgaria;China;Finland;France;Germany;Israel;Italy;Japan;Malaysia;Netherlands;Portugal;Switzerland;United Kingdom;United States
Spesolimab - solution FOR injection
   Boehringer Ingelheim
      2023   Phase 2/Phase 3   NCT05856526   Australia;Austria;Belgium;Bulgaria;China;Finland;France;Germany;Israel;Italy;Japan;Malaysia;Netherlands;Portugal;Switzerland;United Kingdom;United States
SXR1096
   Sixera Pharma
      2022   Phase 1;Phase 2   EUCTR2021-003210-39-AT   Austria;Finland;Germany;Sweden
      2021   Phase 1;Phase 2   EUCTR2021-003210-39-FI   Finland
      -   Phase 1;Phase 2   EUCTR2021-003210-39-SE   Austria;Finland;Germany;Sweden
      -   Phase 1;Phase 2   EUCTR2021-003210-39-DE   Austria;Finland;Germany
Symptomatic therapy
   National Medical Research Center for Children's Health, Russian Federation
      2021   Phase 4   NCT04996485   Russian Federation
TMB-001
   Timber Pharmaceuticals, Inc
      2022   Phase 3   EUCTR2022-000459-35-IT   Canada;France;Germany;Italy;United States
   Timber Pharmaceuticals, LLC
      2022   Phase 3   EUCTR2022-000459-35-FR   Austria;Canada;France;Germany;Italy;Spain;United States
      -   Phase 3   EUCTR2022-000459-35-DE   Canada;France;Germany;Italy;United States
Ustekinumab injection
   National Medical Research Center for Children's Health, Russian Federation
      2021   Phase 4   NCT04996485   Russian Federation
Vehicle
   Aldeyra Therapeutics, Inc.
      2015   Phase 2   NCT02402309   United States
   Novartis Pharmaceuticals
      2011   Phase 1   NCT01428297   France;Germany;Netherlands;United States
   Patagonia Pharmaceuticals, LLC
      2017   Phase 2   NCT02864082   United States
   Quoin Pharmaceuticals
      2022   Phase 2/Phase 3   NCT05521438   United States
   Timber Pharmceuticals LLC
      2019   Phase 2   NCT04154293   Australia;United States
Vehicle OF ADX-102 topical dermal cream
   Aldeyra Therapeutics, Inc.
      2018   Phase 3   NCT03445650   United States
Zileuton
   UMC St Radboud
      2009   Phase 3   EUCTR2009-015895-87-NL   Netherlands
Zyflo CR
   UMC St Radboud
      2009   Phase 3   EUCTR2009-015895-87-NL   Netherlands